Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 4Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 3Cyclophosphamide 3Etoposide 2ibrutinib 1gallium Ga 68 dotatate 1fludarabine 1etoposide phosphate 1belzutifan 1Zoledronic Acid 1Vincristine 1Thiotepa 1Tamoxifen 1Standard of Care 1Radiotherapy 1ONC206 1Nivolumab 1Mesna 1Isotretinoin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Eflornithine 1Drug Therapy 1Cisplatin 1Celecoxib 1Carboplatin 1Blood Specimen Collection 1Automobiles 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroectodermal Tumors, Primitive × Eflornithine × Clear all
NCT06465199 2026-04-13

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡